IP Library Granted Patent US 9,849,142
Granted Patent B2
US 9,849,142 · App. 13/831,396 · Granted Dec 26, 2017

Methods for accelerated return of skin integrity and for the treatment of impetigo

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,849,142
App. No.
13/831,396
Granted
Dec 26, 2017
Kind
B2
Abstract

Methods of treatment and dosage regimes using hydrophobic gel or foam compositions comprising a tetracycline antibiotic for accelerating the return of skin integrity and or in treating or alleviating a disorder including impetigo, acne, rosacea, a skin disease caused by a bacteria or a tetracycline antibiotic responsive disease, wherein the foam composition or gel is administered topically to a target area on a subject having the disorder and wherein the target area comprises an area of skin, or mucosa or an eye.

Claims (23)

1. A method of treating or alleviating impetigo comprising topically administering an effective amount of a tetracycline antibiotic foam to a target area on a mammal in need thereof, wherein the target area comprises an area of skin or mucosa, and wherein the tetracycline antibiotic foam is produced from a foamable composition comprising:

(a) 60% to 90% by weight of at least one hydrophobic oil;

(b) a wax selected from the group consisting of a beeswax, a hydrogenated castor oil, a paraffin wax, a plant wax, an animal wax, a polyethylene wax, and a mixture of two or more thereof;

(c) at least one solid fatty alcohol having a carbon chain length of 14 to 22 carbons;

(d) optionally at least one solid fatty acid having a carbon chain length of 12 to 28 carbons;

(e) a tetracycline antibiotic selected from the group consisting of tetracycline, oxytetracycline, demeclocycline, doxycycline, lymecycline, meclocycline, methacycline, minocycline, rolitetracycline, chlorotetracycline, tigecycline, and a mixture of two or more thereof; and

(f) a liquefied or compressed gas propellant; and

wherein the foamable composition does not comprise a surfactant.

2. The method of claim 1 , wherein the concentration of the liquefied or compressed gas propellant is 3% to 25% by weight of the foamable composition.

3. The method of claim 1 , wherein the wax is selected from the group consisting of a beeswax, a hydrogenated castor oil, and a mixture thereof.

4. The method of claim 1 , wherein the tetracycline antibiotic is present in a free base form, a salt form, a hydrate form, or a complex form.

5. The method of claim 4 , wherein the tetracycline antibiotic is minocycline hydrochloride, and wherein the concentration of minocycline hydrochloride is 0.2% to 10% by weight of the foamable composition.

6. The method of claim 4 , wherein the tetracycline antibiotic is doxycycline hyclate, and wherein the concentration of doxycycline hyclate is 0.2% to 10% by weight of the foamable composition.

7. The method of claim 1 , wherein the tetracycline antibiotic foam is administered twice daily.

8. The method of claim 1 , wherein the hydrophobic oil is selected from the group consisting of a mineral oil, a soybean oil, a coconut oil, cyclomethicone, and a mixture of two or more thereof.

9. The method of claim 1 , wherein the at least one solid fatty alcohol is selected from the group consisting of myristyl alcohol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol, and a mixture of two or more thereof.

10. The method of claim 1 , wherein the foamable composition does comprise the optional at least one solid fatty acid having a carbon chain length of 12 to 28 carbons.

11. The method of claim 10 , wherein the least one solid fatty acid having a carbon chain length of 12 to 28 carbons is stearic acid.

12. The method of claim 1 , wherein the foamable composition further comprises fumed silica.

13. The method of claim 1 , wherein the mammal is a human.

14. The method of claim 1 , wherein tetracycline antibiotic foam is administered at least once daily.

15. The method of claim 1 , wherein the tetracycline antibiotic is micronized.

16. The method of claim 1 , wherein the concentration of tetracycline antibiotic is 0.2 to 10% by weight of the foamable composition.

Assignments (11)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0208 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
CHANGE OF NAME Recorded Jul 30, 2014
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS LTD.
Reel/Frame 033445/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2013
From: TAMARKIN, DOV; GAZAL, ELANA; KEYNAN, RITA; EINI, MEIR; SCHUZ, DAVID
To: FOAMIX LTD.
Reel/Frame 030912/0535 →